Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluoroacetic acid F-18 is a radiolabeled analog of acetate in which the hydrogen atom at the second position is replaced by radioactive fluorine-18. It is primarily under investigation as a positron emission tomography (PET) imaging agent due to its ability to mimic acetate metabolism and allow visualization of metabolic processes in vivo. The compound has a longer radioactive half-life (approximately 110 minutes for fluorine-18), making it suitable for PET imaging procedures. Its mechanism involves cellular uptake and participation in metabolic pathways similar to natural acetate, enabling detection of tissue metabolism and potentially tumor activity during PET scans[1][2][3]. Fluoroacetic acid F-18 is not currently approved for routine clinical use but has been studied in clinical trials as an investigational diagnostic agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluoroacetic acid F-18.